Farnesoid X receptor knockdown provides significant growth inhibition in hepatocellular carcinoma cells while it does not interfere with the proliferation of primary human hepatocyte-derived cells

• Fujino Tomofumi

  Department of Hygiene and Health Sciences, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

• Maruko-Ohtake Akiko

  Department of Radiopharmacy, Tohoku Pharmaceutical University

• Ohtake Yosuke

  Department of Radiopharmacy, Tohoku Pharmaceutical University

• Kobayashi Tomonori

  Department of Radiopharmacy, Tohoku Pharmaceutical University

• Ando Ken

  Department of Hygiene and Health Sciences, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

• Takeuchi Airi

  Department of Hygiene and Health Sciences, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

• Ohkubo Yasuhito

  Department of Radiopharmacy, Tohoku Pharmaceutical University

• Hayakawa Makio

  Department of Hygiene and Health Sciences, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

抄録

Identification of substances with specific toxicity for carcinoma cells promises to facilitate the development of cancer chemotherapeutics that cause minimal side effects. Here, we show that knockdown of the farnesoid X receptor (FXR) effectively suppresses the proliferation of human hepatocellular carcinoma cell lines HepG2 and HLE accompanied by elevated expression of cyclin-dependent kinase (CDK) inhibitor p16/INK4a and p21/Cip1 proteins. On the other hand, the growth of the primary human hepatocyte-derived cell line Fa2N-4 is not affected by the treatment with FXR siRNA irrespective of marked increases in the mRNAs of p16/INK4a and p21/Cip1. Surprisingly, the expression levels of p16/INK and p21/Cip1 proteins are left unchanged in Fa2N-4 cells that are subjected to the FXR siRNA treatment. Since the expression levels of these CDK inhibitor proteins in FXR-knockdown Fa2N-4 cells were elevated in the presence of proteasomal inhibitor MG132, these CDK inhibitors may be subjected to the proteasomal degradation, thereby counteracting the increased expression of their cognate mRNAs, therefore similar levels of p16 and p21 proteins were observed in control and FXR-knockdown Fa2N-4 cells. These results suggest that FXR-knockdown is effective for inhibiting the proliferation of hepatocellular carcinoma cells, not interfering with the regulatory mechanism of normal hepatocyte growth.

収録刊行物

• Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｔｏｘｉｃｏｌｏｇｉｃａｌ　Ｓｃｉｅｎｃｅｓ

  Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｔｏｘｉｃｏｌｏｇｉｃａｌ　Ｓｃｉｅｎｃｅｓ 40 (4), 501-508, 2015

  一般社団法人　日本毒性学会

キーワード

• Farnesoid X receptor
• Cyclin-dependent kinase inhibitors
• Carcinoma-specific cytotoxicity

詳細情報

• CRID: 1390001204905061760
• NII論文ID: 130005087442
• NII書誌ID: AN00002808
• DOI: 10.2131/jts.40.501
• ISSN: 18803989
• ISSN: 03881350
• NDL書誌ID: 026651996
• PubMed: 26165647
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I026651996
• Web Site: https://www.jstage.jst.go.jp/article/jts/40/4/40_501/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2016128344
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可